Aciont
Envisioning the Future of Ocular Therapeutics
About Us | Unmet Needs | Technologies | Product Pipeline | Media & Investors
Technologies

Sample Illustrations

Novel Complexation Formation Method

While the Visulex® device thwarts the eye’s surface clearance effects, it alone does not adequately address the eye’s internal clearance effects. By increasing the residence time of the drug within or around the transscleral pathway, the retarded clearance from the tissue will create a depot effect that will optimally present a therapeutically relevant drug concentration to the eye’s interior (e.g., retina/choroid) yielding a superior pharmacodynamic effect (at least in the case of our preclinical ocular inflammation treatment models).

A sample Visulex® applicator worn by a rabbit.
 

An investigative agent is delivered non-invasively and precipitates inside the eye (e.g. sclera) with a simultaneously delivered counterion.

Real Time Illustration of Transscleral Drug Delivery

The illustration below shows how a water soluble contrast agent migrates to the posterior pole of the eye from a Visulex® non-invasive drug delivery system.


These MRI photos illustrates in real time how a molecule can be delivered non-invasively using the Visulex® system and transported to the posterior section of the eye. In this case a steroid-contrast agent complex depot was formed (high concentration shown in dark black) and the agent migrated transsclerally allowing the contrast agent to slowly diffuse from the depot to the posterior regions of the eye (diffused level concentrations shown in bright light).